IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Loughney et al.) I hereby certify that this paper is being
) deposited with the United States Postal
Serial No.: To be assigned) Service on December 20, 2001 , in an
) envelope addressed to the Commissioner for
Filed: Herewith) Patents, Washington, D.C. 20231 utilizing
) the "Express Mail Post Office Addressee"
For: Phosphodiesterase 10) service of the United States Postal Service
) Under Mailing Label No. EK657816282US
Group Art: To be assigned)
) Date: December 20, 2001
Examiner: To be assigned	
) Lichaul fimme
) Richard Zimmermann

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

Prior to examination on the merits, please enter the following preliminary amendment.

In the specification:

At page 1, under the Title and before the heading "Field of the Invention," please delete the priority claim and insert the following updated priority claim:

--This application is a divisional application of U.S. patent application Serial No: 09/256,000 filed February 23, 1999, which claims priority of U.S. Provisional Application No. 60/075,508, filed February 23, 1998.--

In the claims:

Please cancel claims 3-33 and add new claim 34 as follows:

- 34. A human PDE10 polypeptide encoded by a polynucleotide selected from the group consisting of:
 - a) the polynucleotide encoding the polypeptide according to claim 2, and
 - b) a polynucleotide which hybridizes to the non-coding strand of the polynucleotide of (a) under moderately stringent hybridization conditions which include a final wash in 2X SSC and 0.1% SDS at 65°C.

REMARKS

The specification is amended to include the priority claim to the parent application. A marked-up version of the specification is set out in Appendix B hereto.

Claims 1-2 relate to a purified and isolated polypeptide of the present invention. Claims 1-2 represent a previously designated restriction group during the prosecution of the parent patent application. Support for new claim 34 is found in the specification at page 4, lines 5-17. Upon entry of the present amendment, pending claims in the application will read as set out in Appendix A hereto.

The Applicant does not intend by these claim amendments or any other amendments to abandon the subject matter of any claim as originally filed or as later presented. The Applicant reserves the right to pursue such subject matter in subsequent applications, such as continuations, CIP's, and divisionals. The amendments include no new matter.

Filed herewith is a corrected Sequence Listing and computer readable copy of the Sequence Listing that correct errors which were identified during the prosecution of the

parent patent application. I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN 6300 Sears Tower 233 South Wacker Drive Chicago, Illinois 60606-6357 (312) 474-6300

By:

Joseph A. Williams, Jr.

Reg. No. 38,659

December 20, 2001

APPENDIX A

Pending claims

- 1. A purified and isolated PDE10 polypeptide.
- 2. The polypeptide according to claim 1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22.
- 34. A human PDE10 polypeptide encoded by a polynucleotide selected from the group consisting of:
 - a) the polynucleotide according to claim 2, and
 - b) a polynucleotide which hybridizes to the non-coding strand of the polynucleotide of (a) under moderately stringent hybridization conditions which include a final wash in 2X SSC and 0.1% SDS at 65°C.

APPENDIX B

Amendments to the specification

At page 1, line 2:

This application is a divisional application of U.S. patent application Serial No: 09/256,000 filed February 23, 1999, which [This Application] claims priority of U.S. Provisional Application No. 60/075,508, filed February 23, 1998.